HEALTH UTILITIES ASSOCIATED WITH HYPOGLYCEMIC EVENTS IN TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS RECEIVING BASAL-BOLUS INSULIN THERAPY

被引：1
|
作者：
Ionova, T. [1 ]
Nikitina, T. [1 ]
Kurbatova, K. [2 ]
机构：
[1] Natl Pirogov Med Surg Ctr, Moscow, Russia
[2] Multinatl Ctr Qual Life Res, St Petersburg, Russia
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2112
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB73
引用
收藏
页码：A610 / A610
页数：1
相关论文
共 50 条
  • [41] Insulin requirement profiles in Japanese hospitalized subjects with type 2 diabetes treated with basal-bolus insulin therapy
    Shimoda, Seiya
    Okubo, Mina
    Koga, Kotaro
    Sekigami, Taiji
    Kawashima, Junji
    Kukidome, Daisuke
    Igata, Motoyuki
    Ishii, Norio
    Shimakawa, Akiko
    Matsumura, Takeshi
    Motoshima, Hiroyuki
    Furukawa, Noboru
    Nishida, Kenro
    Araki, Eiichi
    ENDOCRINE JOURNAL, 2015, 62 (02) : 209 - 216
  • [42] Comparison of canagliflozin and liraglutide as a replacement for bolus insulin in type 2 diabetes patients well-controlled by basal-bolus insulin
    Kumashiro, N.
    Ando, Y.
    Shigiyama, F.
    Igarashi, H.
    Yoshikawa, F.
    Uchino, H.
    Yoshino, H.
    Miyagi, M.
    Ikehara, K.
    Hirose, T.
    DIABETOLOGIA, 2018, 61 : S126 - S126
  • [43] THE COSTS OF INTENSIFICATION FROM BASAL INSULIN TO BASAL-BOLUS IN TYPE 2 DIABETES: A SURVEY OF PHYSICIANS
    Pfeiffer, K. M.
    Basse, A.
    Brod, M.
    VALUE IN HEALTH, 2018, 21 : S74 - S74
  • [44] Pharmacogenomics and pharmacomicrobiomics in type 2 diabetes mellitus (T2DM)
    Luo, Jian-Quan
    Shu, Yan
    Zhang, Wei
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [45] Vascular responsiveness in type 2 diabetes mellitus (T2DM)
    Blum, A.
    Socea, D.
    Sirchan, R.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2016, 109 (12) : 791 - 796
  • [46] The platelets characteristics in type 2 diabetes mellitus (T2DM)
    Buryachkovskaya, L.
    Uchitel, I. A.
    Sumarokov, A. B.
    Docenko, U., V
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 931 - 931
  • [47] Microvascular complications in type 2 diabetes mellitus (T2DM).
    Cheung, AT
    Ramanujam, S
    Duong, PL
    Schauer, D
    Chan, LS
    Dwyre, DM
    Larkin, EC
    FASEB JOURNAL, 2002, 16 (04): : A208 - A208
  • [48] ACHIEVEMENT OF GLYCAEMIC TARGETS WITH CANAGLIFLOZIN IN TRIPLE THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Diels, J.
    Schubert, A.
    Hamilton, G.
    Canovatchel, W.
    VALUE IN HEALTH, 2015, 18 (07) : A598 - A598
  • [49] LITERATURE REVIEW OF ECONOMIC AND CLINICAL OUTCOMES ASSOCIATED WITH MULTIPLE DAILY INSULIN INJECTION (MDI) THERAPY FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Mathur, I
    Trenery, A.
    Simon, A.
    Gala, S.
    Ermakova, A.
    Weiss, M.
    Taylor, S.
    VALUE IN HEALTH, 2019, 22 : S149 - S149
  • [50] Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM)
    Fonseca, Vivian
    Dejager, Sylvie
    Albrecht, Diego
    Shirt, Lynda
    Schweizer, Anja
    DIABETES, 2006, 55 : A111 - A111
12345